Athira Pharma (ATHA) restores Nasdaq listing compliance after meeting $1.00 bid

Rhea-AI Filing Summary

Athira Pharma, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received a notice on October 16, 2024 that its common stock had closed below $1.00 per share for 30 consecutive business days, triggering a deficiency under Nasdaq’s minimum bid requirement.

Nasdaq has now informed Athira that the closing bid price of its common stock was at least $1.00 per share for ten consecutive business days as of October 2, 2025. As a result, Athira is again in compliance with the minimum bid rule and Nasdaq has closed the deficiency matter.

Insights

Equity markets & listing standards analyst

Athira eliminates an active Nasdaq listing deficiency by meeting the $1.00 bid requirement.

Athira Pharma confirms that its common stock has closed at or above $1.00 per share for ten straight trading days as of October 2, 2025. This cures a prior deficiency that arose when the stock traded below $1.00 for 30 consecutive business days, breaching Nasdaq’s minimum bid rule.

Regaining compliance removes the immediate risk of delisting tied to that specific rule, which can be important for maintaining liquidity and institutional ownership. The notice also states that Nasdaq considers the matter closed, so no ongoing remediation related to this bid-price issue is in place based on this information.

Future developments will depend on Athira’s ability to keep its share price at compliant levels and on its overall adherence to other Nasdaq listing criteria, which would be addressed in subsequent company disclosures if needed.

false000162046300016204632025-10-022025-10-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2025

Athira Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39503	45-3368487
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

18706 North Creek Parkway, Suite 104
Bothell, WA 98011

(Address of principal executive offices, including zip code)

(425) 620-8501

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	ATHA	The Nasdaq Stock Market LLC  (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐).

Item 8.01. Other Events.

As previously reported, on October 16, 2024, Athira Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for the Company’s common stock (the “Common Stock”) had fallen below $1.00 per share for 30 consecutive business days, which is the minimum closing bid price required to maintain listing on The Nasdaq Stock Market under applicable Nasdaq Listing Rules (the “Minimum Bid Requirement”).

On October 2, 2025, the Company received written notice from Nasdaq notifying the Company that since the closing bid price for the Common Stock was $1.00 per share or greater for ten consecutive business days, the Company has regained compliance with the Minimum Bid Requirement and this matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Athira Pharma, Inc.
Date:	October 3, 2025	By:	/s/ Mark Litton
			Mark Litton
			President and Chief Executive Officer

FAQ

What did Athira Pharma, Inc. (ATHA) announce in this 8-K?

Athira Pharma, Inc. announced that it has regained compliance with Nasdaq’s minimum bid price requirement after its common stock closed at or above $1.00 per share for ten consecutive business days as of October 2, 2025.

Why was Athira Pharma (ATHA) previously non-compliant with Nasdaq rules?

Athira was previously non-compliant because, as reported earlier, the closing bid price of its common stock was below $1.00 per share for 30 consecutive business days, which violated Nasdaq’s minimum bid price requirement.

What is Nasdaq’s minimum bid price requirement mentioned for ATHA?

Nasdaq’s minimum bid price requirement, as applied here, is that a company’s common stock must have a closing bid price of at least $1.00 per share to maintain its listing under the applicable Nasdaq Listing Rules.

How did Athira Pharma (ATHA) regain compliance with Nasdaq?

Athira Pharma regained compliance when the closing bid price of its common stock was $1.00 per share or greater for ten consecutive business days, leading Nasdaq to confirm that the company again meets the minimum bid price standard.

What is the current status of Athira Pharma’s Nasdaq listing issue?

Nasdaq notified Athira that the company has regained compliance with the minimum bid price rule and that the bid-price deficiency matter is now closed.

Does this 8-K for Athira Pharma (ATHA) discuss any financial results?

No. This disclosure focuses on Athira Pharma’s listing compliance status with Nasdaq’s minimum bid price rule and does not present financial results.